Re: Potential ROW Partnership for MIRV?
Marketing, sales or licensing agreements Typically come after FDA approval. Need the label clearly defined to
Determine the TAM. partnerships prior to an fda are based on co-development of the product to defray costs. IMGN situation for MIrve situation is the prior where 632 was the later. Since most of our combo therapies are generic, we will most likely partner with a PARP partner like AZ or Glaxo that wants to own the ovarian channel or a distributor of generic chemo therapies is my guess. Seeing that they need money, an outright acquisition is most certainly on the table. In an acquisition Woukd be a suitor that has both an HBOC and AML sales force.